Literature DB >> 978134

Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

R G Medicus, O Götze, H J Müller-Eberhard.   

Abstract

In this study the physiological role of properdin and the differential subunit composition of the solid phase enzymes of the pathway have been explored. Cell-bound C3 and C5 convertase differ in their C3b requirement. Apparently one molecule of C3b is sufficient to allow formation of C3 convertase (C3b,B), whereas two or more are required for generation of C5 convertase (C3bn,B). This conclusion was drawn from results indicating the critical role of the spacial distribution of C3b molecules on the cell surface in enzyme formation. While the C3/C5 convertase is fully capable of acting on C5 and thereby initiating the assembly of the cytolytic membrane attack complex, it is exceedingly labile and vulnerable to destruction by the C3b inactivator. It is the apparent role of properdin to confer a degree of stability upon the labile enzyme and to protect its C3 convertase function against enzymatic destruction. To achieve these effects, precursor properdin (pre-P) is recruited in a binding-activation reaction by the labile C3/C5 convertase. Multiple C3b molecules appear to be needed for the formation of properdin-activating principle. Three modes of regulation have been described, which involve spontaneous dissociation enzymatic degradation by C3b inactivator and disassembly by beta1H. The functional differences of pre-P and activated properdin (P) were delineated, pre-P displaying a weak affinity for C3b and P the capacity of strong interaction, P generating a soluble C3 convertase in serum and pre-P being unable to do so. Because of the profound differences between native pre-P and the laboratory product P, the question was raised as to whether soluble P represents an unphysiological form of the protein. On the basis of this and other studies, the conclusion was reached that in vitro properdin recruitment constitutes the terminal event of the properdin pathway, and that properdin augments the function of C3/C5 convertase without changing its substrate specificity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 978134      PMCID: PMC2190426          DOI: 10.1084/jem.144.4.1076

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

2.  The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.

Authors:  A E Stitzel; R E Spitzer
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

3.  Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.

Authors:  D T Fearon; K F Austen; S Ruddy
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

4.  Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement.

Authors:  J Chapitis; I H Lepow
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

5.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

6.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

7.  A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.

Authors:  E H Vallota; O Götze; H L Spiegelberg; J Forristal; C D West; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

8.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

9.  Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.

Authors:  R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  67 in total

1.  Classical and alternative complement pathway activation by pneumococci.

Authors:  C G Stephens; R C Williams; W P Reed
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

Review 2.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

3.  Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.

Authors:  Dennis E Hourcade; Lynne M Mitchell
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

4.  Properdin binding to complement activating surfaces depends on initial C3b deposition.

Authors:  Morten Harboe; Christina Johnson; Stig Nymo; Karin Ekholt; Camilla Schjalm; Julie K Lindstad; Anne Pharo; Bernt Christian Hellerud; Kristina Nilsson Ekdahl; Tom Eirik Mollnes; Per H Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

5.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

6.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

Authors:  R D Schreiber; M K Pangburn; P H Lesavre; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

7.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

Review 8.  Properdin: New roles in pattern recognition and target clearance.

Authors:  Claudia Kemper; Dennis E Hourcade
Journal:  Mol Immunol       Date:  2008-08-08       Impact factor: 4.407

9.  The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.

Authors:  R G DiScipio
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

10.  Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.

Authors:  J T Mayes; R D Schreiber; N R Cooper
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.